In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 Lars Ryden
Speaker
Lars Ryden
Lars Ryden Lars Ryden

Karolinska Institute, Stockholm (Sweden)

Specialities : Risk Factors and Prevention , Coronary Artery Disease Chronic

Lars Rydén, Senior Professor of Cardiology at the Karolinska Institute, Sweden, specialised in internal medicine and cardiology. His research focus on arrhythmias, cardiac pacing, heart failure and diabetes-related cardiovascular disease. He published more than 700 artticles. He is Dr h.c. at Katowice University, Poland, and an honorary member of the Royal College of Physicians, UK and served as the President of the Swedish Cardiac Society and chaired the Scientific Board of the Swedish Heart Lung Foundation. He was the President of the European Society of Cardiology (ESC), and member of the board of World Heart Federation. He chaired numerous expert groups in collaboration with the ESC and European Commission and the group that produced the European Heart Health Charter and The Chronic Disease Alliance – A Unified Prevention Approach. Professor Rydén chaired the Task Forces of the 2007 and 2013 ESC/European Association for the Study of Diabetes (EASD) Guidelines for Diabetes.

49 presentations from this speaker

Diabetes: new therapeutic strategies, glucose and risk factor control.

Event : Webinar 2020

  • Session : EAPC Webinars 2020
  • Speaker : F Cosentino (Stockholm,SE), L Mellbin (Bromma,SE), L Ryden (Stockholm,SE)

Chair’s Welcome

Event : ESC Congress 2019

  • Session : Multi-dimensional glucagon-like peptide-1 receptor agonists — Positioning their role in treatment of type 2 diabetes and cardiovascular disease
  • Speaker : L Ryden (Stockholm,SE)
  • Sponsored by Novo Nordisk A/S

Chair's welcome

Event : ESC Congress 2019

  • Session : Improving cardiovascular risk in patients with obesity
  • Speaker : L Ryden (Stockholm,SE)
  • Sponsored by Novo Nordisk A/S

Connecting with the speakers - Questions and answers

Event : ESC Congress 2019

  • Session : Improving cardiovascular risk in patients with obesity
  • Speaker : L Ryden (Stockholm,SE), N Sattar (Glasgow,GB), E Bohula (Boston,US)
  • Sponsored by Novo Nordisk A/S

Connecting with the speakers - Questions and answers

Event : ESC Congress 2019

  • Session : Multi-dimensional glucagon-like peptide-1 receptor agonists — Positioning their role in treatment of type 2 diabetes and cardiovascular disease
  • Speaker : L Ryden (Stockholm,SE), S Verma (Toronto,CA), M Kosiborod (Kansas,US)
  • Sponsored by Novo Nordisk A/S

Diabetes: behavioural changes, lifestyle management, compliance.

Event : Webinar 2019

  • Session : EAPC Webinars 2019
  • Speaker : C Jennings (London,GB), L Ryden (Stockholm,SE), F Snoek (,NL)

Examining the link: type 2 diabetes and cardiovascular disease

Event : ESC Congress 2019

  • Session : Multi-dimensional glucagon-like peptide-1 receptor agonists — Positioning their role in treatment of type 2 diabetes and cardiovascular disease
  • Speaker : L Ryden (Stockholm,SE)
  • Sponsored by Novo Nordisk A/S

Metabolic syndrome, lifestyle background and modification.

Event : Webinar 2019

  • Session : EAPC Webinars 2019
  • Speaker : PM Nilsson (Dalby,SE), L Ryden (Stockholm,SE), J Tuomilehto (Helsinki,FI)

Risk scoring is essential for cardiovascular disease prevention - CON

Event : ESC Congress 2019

  • Session : To score or not to score risk assessment in primary prevention
  • Speaker : L Ryden (Stockholm,SE)

The clinical interplay of Diabetes Mellitus and heart failure.

Event : ESC Congress 2019

  • Session : Diabetes and heart failure: a complex relationship
  • Speaker : L Ryden (Stockholm,SE)

The major threat of our time: the global interrelation between obesity, type 2 diabetes and cardiovascular disease

Event : ESC Congress 2019

  • Session : Improving cardiovascular risk in patients with obesity
  • Speaker : L Ryden (Stockholm,SE)
  • Sponsored by Novo Nordisk A/S

Discussion - GLP-1 RA in diabetes and cardiovascular disease - What are the key opportunities for cardiology practice

Event : ESC Congress 2018

  • Session : Outcomes of GLP-1 RA in diabetes and cardiovascular disease - Discussing the key opportunities for cardiology practice
  • Speaker : TF Luscher (London,GB), L Ryden (Stockholm,SE), S Jacob (Villingen,DE)
  • Organised by PACE-CME, Physicians' Academy for Cardiovascular Education, supported with an educational grant from Novo Nordisk

Discussion - Preventing cardiovascular disease in patients with T2DM: how to apply novel outcome data with GLP-1 ra to clinical practice.

Event : ESC Preventive Cardiology (Formerly EuroPrevent) 2018

  • Session : Preventing cardiovascular disease in patients with T2DM: how to apply novel outcome data with GLP-1 ra to clinical practice.
  • Speaker : DE Grobbee (Utrecht,NL), R Hobbs (Oxford,GB), L Ryden (Stockholm,SE)
  • Sponsored by PACE-CME: Physicians' Academy for Cardiovascular Education, supported with an educational grant by Novo Nordisk.

Identifying and managing dysglycaemia and diabetes.

Event : ESC Preventive Cardiology (Formerly EuroPrevent) 2018

  • Session : What is new in the management of people with CHD? EUROASPIRE V survey on cardiovascular disease prevention and diabetes
  • Speaker : L Ryden (Stockholm,SE)

Practical management of cardiovascular risk: lessons from latest diabetes trials.

Event : ESC Preventive Cardiology (Formerly EuroPrevent) 2018

  • Session : Preventing cardiovascular disease in patients with T2DM: how to apply novel outcome data with GLP-1 ra to clinical practice.
  • Speaker : L Ryden (Stockholm,SE)
  • Sponsored by PACE-CME: Physicians' Academy for Cardiovascular Education, supported with an educational grant by Novo Nordisk.

Screening for diabetes in patients with coronary artery disease – How should it be done?

Event : ESC Congress 2018

  • Session : Implementation of cardiovascular disease prevention in daily practice - Insights from EUROASPIRE V
  • Speaker : L Ryden (Stockholm,SE)

Summary - Translating GLP-1 trial outcomes to cardiology practice - Which patients will benefit?

Event : ESC Congress 2018

  • Session : Outcomes of GLP-1 RA in diabetes and cardiovascular disease - Discussing the key opportunities for cardiology practice
  • Speaker : L Ryden (Stockholm,SE)
  • Organised by PACE-CME, Physicians' Academy for Cardiovascular Education, supported with an educational grant from Novo Nordisk

The global burden of diabetes.

Event : ESC Congress 2018

  • Session : Cardiovascular prevention in diabetes
  • Speaker : L Ryden (Stockholm,SE)
  • European Association of Preventive Cardiology (EAPC)

Translating GLP-1 trial outcomes to cardiology practice: which patients will benefit? .

Event : ESC Congress 2018

  • Session : Outcomes of GLP-1 RA in diabetes and cardiovascular disease: what are the key opportunities for cardiology practice? (EBAC Accredited)
  • Speaker : L Ryden (Stockholm,SE)
  • Organised by PACE-CME, Physicians' Academy for Cardiovascular Education, supported with an educational grant from Novo Nordisk

Use of incretin-based therapies.

Event : ESC Congress 2018

  • Session : How do SGLT2 inhibitors and incretin-based therapy exert their effects on cardiovascular disease?
  • Speaker : L Ryden (Stockholm,SE)
  • Joint with the European Association for the Study of Diabetes

Cardiovascular outcome trials in type 2 diabetes: lessons learned and questions to ask.

Event : ESC Congress 2017

  • Session : Cardiovascular disease prevention with antihyperglycaemic and cholesterol lowering therapy in type 2 diabetes
  • Speaker : L Ryden (Stockholm,SE)

Interactive discussions - GLP-1 receptor agonists and CV risk management in type 2 diabetes: a new treatment paradigm?

Event : ESC Congress 2017

  • Session : GLP-1 receptor agonists and cardiovascular risk management in type 2 diabetes: a new treatment paradigm?
  • Speaker : L Ryden (Stockholm,SE), M Husain (Toronto,CA), M Pfeffer (Boston,US)
  • Sponsored by Novo Nordisk

Introduction - GLP-1 receptor agonists and CV risk management in type 2 diabetes: a new treatment paradigm?

Event : ESC Congress 2017

  • Session : GLP-1 receptor agonists and cardiovascular risk management in type 2 diabetes: a new treatment paradigm?
  • Speaker : L Ryden (Stockholm,SE)
  • Sponsored by Novo Nordisk

Introduction: cardiovascular disease in type 2 diabetes – Where do we come from.

Event : ESC Congress 2017

  • Session : Improving cardiovascular outcomes in type 2 diabetes: a novel role for GLP-1 receptor agonists?
  • Speaker : L Ryden (Stockholm,SE)
  • Sponsored by Novo Nordisk

Panel discussion - Improving CV outcomes in type 2 diabetes: A novel role for GLP-1 receptor agonists?

Event : ESC Congress 2017

  • Session : Improving cardiovascular outcomes in type 2 diabetes: a novel role for GLP-1 receptor agonists?
  • Speaker : L Ryden (Stockholm,SE), J Plutzky (Boston,US), N Poulter (London,GB)
  • Sponsored by Novo Nordisk

Perspectives on results from recent CVOTs in type 2 diabetes.

Event : ESC Congress 2017

  • Session : Improving cardiovascular outcomes in type 2 diabetes: a novel role for GLP-1 receptor agonists?
  • Speaker : L Ryden (Stockholm,SE)
  • Sponsored by Novo Nordisk

Roundtable discussion: what can we learn from current guidelines – Do they accurately reflect current knowledge and what can we expect over time?

Event : ESC Congress 2017

  • Session : A closer look at glucose lowering agents cardiovascular safety results and current heart failure guidelines
  • Speaker : E Peterson (Durham,US), L Ryden (Stockholm,SE)
  • Sponsored by MSD

Treatment aims of glucose lowering drugs in patients with type 2 diabetes

Event : ESC Congress 2017

  • Session : Treatment of type 2 diabetes - Important new aspects for the cardiologist
  • Speaker : L Ryden (Stockholm,SE)
  • Joint with the European Association for the Study of Diabetes

Closing the gap: the EUROASPIRE study (European Action on Secondary Prevention by Intervention to Reduce Events) and what it can tell us for the treatment of diabetes patients.

Event : ESC Congress 2016

  • Session : Clinical considerations for cardiologists: exploring the evidence for primary and secondary prevention in type 2 diabetes
  • Speaker : L Ryden (Stockholm,SE)
  • Sponsored by MSD

Introduction - Cardiovascular risk in diabetes and cardiovascular outcomes trials - Where do we come from?

Event : ESC Congress 2016

  • Session : Addressing cardiovascular risk in type 2 diabetes - The LEADER trial
  • Speaker : L Ryden (Stockholm,SE)
  • Sponsored by Novo Nordisk

Q&A - Clinical considerations for cardiologists: exploring the evidence for primary and secondary prevention in type 2 diabetes.

Event : ESC Congress 2016

  • Session : Clinical considerations for cardiologists: exploring the evidence for primary and secondary prevention in type 2 diabetes
  • Speaker : N Marx (Aachen,DE), PW Armstrong (Alberta,CA), L Leiter (Toronto,CA), L Ryden (Stockholm,SE)
  • Sponsored by MSD

Question and answers - Addressing cardiovascular risk in type 2 diabetes - The LEADER trial.

Event : ESC Congress 2016

  • Session : Addressing cardiovascular risk in type 2 diabetes - The LEADER trial
  • Speaker : L Ryden (Stockholm,SE)
  • Sponsored by Novo Nordisk

Diabetes and cardiovascular disease - From EuroAspire to GlobalAspire?

Event : ESC Congress 2015

  • Session : Economic environment in cardiovascular outcome
  • Speaker : L Ryden (Stockholm,SE)
  • ESC and the Cardiological Society of India

Diabetes.

Event : ESC Congress 2015

  • Session : Co-morbidities in heart failure - An overview
  • Speaker : L Ryden (Stockholm,SE)

Identifying and managing dysglycaemia and diabetes.

Event : ESC Congress 2015

  • Session : How are we managing cardiovascular risk in the primary care environment? EUROASPIRE IV survey
  • Speaker : L Ryden (Stockholm,SE)

State of the Art in diabetes management .

Event : ESC Congress 2015

  • Session : Diabetes management: the way to control atherosclerosis
  • Speaker : L Ryden (Stockholm,SE)

ADVANCE-ON: Discussant review

Event : ESC Congress 2014

  • Session : Clinical Trial Update Hot Line: Interventions and drug therapy
  • Speaker : L Ryden (Stockholm,SE)

BB-meta-HF: Discussant review

Event : ESC Congress 2014

  • Session : Clinical Trial Update Hot Line: Stable CAD and atrial fibrillation
  • Speaker : L Ryden (Stockholm,SE)

Effects on blood pressure and potential mechanisms related to CV protection.

Event : ESC Congress 2014

  • Session : Treatment of diabetes with SGLT2 inhibitors: potentials for CV risk reduction
  • Speaker : L Ryden (Stockholm,SE)
  • Sponsored by Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group

Lessons learnt from glitazones.

Event : ESC Congress 2014

  • Session : Cardiovascular safety of antidiabetic drugs
  • Speaker : L Ryden (Stockholm,SE)

Type II diabetes and cardiovascular disease: what do the Guidelines say?

Event : ESC Congress 2014

  • Session : Drug therapy: when guidelines do not have all the answers
  • Speaker : L Ryden (Stockholm,SE)

What do the ESC Guidelines recommend as best management?

Event : ESC Congress 2014

  • Session : Diabetes and cardiovascular disease: lessons from EUROASPIRE IV
  • Speaker : L Ryden (Stockholm,SE)

Diabetes in cardiovascular disease: questions and answers to the panellists.

Event : ESC Congress 2013

  • Session : Meet the Guidelines Task Force II
  • Speaker : L Ryden (Stockholm,SE), PJ Grant (Leeds,GB)

Diabetes, pre-diabetes in cardiovascular disease.

Event : ESC Congress 2013

  • Session : ESC Guidelines 2013 overview
  • Speaker : L Ryden (Stockholm,SE), PJ Grant (Leeds,GB)

Guidelines 2013 - what’s hot and what’s not.

Event : ESC Congress 2013

  • Session : ESC Guidelines on diabetes, pre-diabetes and cardiovascular disease
  • Speaker : L Ryden (Stockholm,SE)

Panel discussion: redefining the future for cardiovascular disease management in type 2 diabetes

Event : ESC Congress 2013

  • Session : Redefining the future for cardiovascular disease management in type 2 diabetes
  • Speaker : L Ryden (Stockholm,SE), J Davidson (Dallas,US), E Mannucci (Firenze,IT), L Leiter (Toronto,CA), P Steg (Paris,FR)
  • Sponsored by Bristol-Myers Squibb and AstraZeneca

Presentation of the awardee.

Event : ESC Congress 2013

  • Session : ESC Geoffrey Rose Lecture on Population Sciences
  • Speaker : L Ryden (Stockholm,SE)

The need for continuous evaluation of guideline implementation.

Event : ESC Congress 2013

  • Session : EUROASPIRE IV - principal results
  • Speaker : L Ryden (Stockholm,SE)

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are